Roche will no longer progress emugrobart to late-stage trials in FSHD and SMA, as the drug has failed to demonstrate ...

The START Center for Cancer Research (START) has partnered with Trialing, aimed at increasing oncology clinical trial access ...

YolTech Therapeutics has received clearance from the US FDA to begin a Phase II/III clinical study of its in vivo ...

Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF" time in patients with Parkinson’s disease.

Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone receptor agonist has met its primary endpoints in a Phase III trial. In the ...

Mirum Pharmaceuticals has completed enrolment in the Phase III EXPAND study assessing Livmarli in rare cholestatic liver ...

The FDA's guidance clarifies what sponsors should consider when putting together an application for the validation of a NAM approach.

EnteroBiotix has completed enrolment in the Phase IIa MAST trial of EBX-102-02 in patients undergoing allo-HSCT for ...

GEN Pharmaceuticals has secured the BEBO Foundation approval for the assessment of ethics of biomedical research to initiate a Phase II clinical trial in the Netherlands of its new drug, SUL-238, for ...

Analysts are intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they say it's too early assess its market potential against orforglipron.

J&J has reported encouraging results from a Phase I study of the investigational intravesical drug-releasing system, Erda-iDRS, in patients with intermediate- and high-risk NMIBC harbouring select ...

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing DMTs for Parkinson’s disease.